These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R Front Immunol; 2023; 14():1004795. PubMed ID: 37033984 [TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of anti-CD20 "what do B-cells do?". Eisenberg R; Looney RJ Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773 [TBL] [Abstract][Full Text] [Related]
13. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Treon SP; Anderson KC Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004 [TBL] [Abstract][Full Text] [Related]
14. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020 [TBL] [Abstract][Full Text] [Related]
15. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. Stübgen JP J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837 [TBL] [Abstract][Full Text] [Related]
16. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121. Taupin P Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688 [TBL] [Abstract][Full Text] [Related]